| BCBS Oklahoma Medical Policies | Ocrelizumab or Ocrelizumab and Hyaluronidase-ocsq | 2026-04-01 |
| BCBS Oklahoma Medical Policies | Temporarily Implanted Nitinol Device (iTind) for Benign | 2026-04-01 |
| BCBS Oklahoma Medical Policies | Teplizumab-mzwv | 2026-04-01 |
| BCBS Oklahoma Medical Policies | Teprotumumab-trbw | 2026-04-01 |
| BCBS Oklahoma Medical Policies | Tocilizumab and Associated Biosimilar(s) | 2026-04-01 |
| BCBS Oklahoma Medical Policies | Triamcinolone acetonide | 2026-04-01 |
| BCBS Oklahoma Medical Policies | Unicondylar Interpositional Spacer as a Treatment of | 2026-04-01 |
| BCBS Oklahoma Medical Policies | Vedolizumab | 2026-04-01 |
| BCBS Texas Medical Policies | Abatacept | 2026-04-01 |
| BCBS Texas Medical Policies | Anifrolumab-fnia | 2026-04-01 |